Table 3 Association between clinical and pathological characteristics with progression free survival (PFS) in 92 patients treated with paclitaxel without bevacizumab.

From: A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients

Characteristics

N (92)

PFS

HR

95% CI

p

ECOG PS

0

65

0.657

 

0.0015

 

1

19

0.506

0.381–1.608

0.82

 

2

5

0.587

0.475–3.730

0.41

 

NA

3

–

–

–

Hormonal receptor

Negative

9

   
 

Positive

83

1.326

0.635–2.771

0.453

DFI

<12 months

31

   
 

≥12 months

61

1.534

0.980–2.401

0.061

Sites involvement

<3

74

   
 

≥3

18

1.376

0.806–2.350

0.242

Adjuvant CHT

Yes

50

1.569

1.001–2.457

0.049

 

No

42

   

Adjuvant taxanes

Yes

21

2.138

0.283–3.562

0.004

 

No

71

   

Visceral disease

Yes

54

2.036

1.289–3.215

0.002

 

No

38

   
  1. CHT chemotherapy, DFI disease-free interval, HR hazard ratio, NA not assessable.
Back to article page